BlackRock Inc. bought a new stake in Isotechnika Pharma Inc. (NASDAQ:AUPH) (TSE:AUP) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 719,713 shares of the biotechnology company’s stock, valued at approximately $3,261,000. BlackRock Inc. owned approximately 0.86% of Isotechnika Pharma at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of the stock. Ameriprise Financial Inc. boosted its stake in Isotechnika Pharma by 39.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 211,569 shares of the biotechnology company’s stock valued at $1,327,000 after purchasing an additional 60,101 shares during the last quarter. Swiss National Bank acquired a new position in Isotechnika Pharma during the 4th quarter valued at about $421,000. Cutler Capital Management LLC boosted its stake in Isotechnika Pharma by 25.0% during the 4th quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock valued at $226,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Isotechnika Pharma by 13,197.5% during the 3rd quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 26,395 shares during the last quarter. 28.58% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have issued reports on the company. Cantor Fitzgerald reiterated a “buy” rating and set a $16.00 price target on shares of Isotechnika Pharma in a research note on Wednesday. BidaskClub upgraded Isotechnika Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Isotechnika Pharma in a research note on Wednesday, May 2nd. Zacks Investment Research downgraded Isotechnika Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, April 11th. Finally, Seaport Global Securities reiterated a “buy” rating and set a $11.00 price target on shares of Isotechnika Pharma in a research note on Friday, March 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Isotechnika Pharma presently has a consensus rating of “Buy” and a consensus price target of $10.92.
Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, May 10th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Isotechnika Pharma had a negative return on equity of 20.67% and a negative net margin of 8,193.08%. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.05 million. research analysts expect that Isotechnika Pharma Inc. will post -0.69 earnings per share for the current fiscal year.
Isotechnika Pharma Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.
Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.